A Nomogram to Predict the Pathologic Complete Response of Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer Based on Simple Laboratory Indicators

被引:30
|
作者
Zhang, Fanrong [1 ,2 ]
Huang, Minran [3 ]
Zhou, Huanhuan [1 ,4 ]
Chen, Kaiyan [1 ,4 ]
Jin, Jiaoyue [1 ,5 ]
Wu, Yingxue [1 ,5 ]
Ying, Lisha [1 ,5 ]
Ding, Xiaowen [1 ,2 ]
Su, Dan [1 ,5 ]
Zou, Dehong [1 ,2 ]
机构
[1] Chinese Acad Sci, Inst Canc Res & Basic Med Sci, Hangzhou, Zhejiang, Peoples R China
[2] Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp, Dept Breast Surg, Hangzhou, Zhejiang, Peoples R China
[3] Zhejiang Chinese Med Univ, Clin Med Coll 2, Dept Oncol, Hangzhou, Zhejiang, Peoples R China
[4] Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp, Dept Chemotherapy, Hangzhou, Zhejiang, Peoples R China
[5] Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp, Dept Pathol, Hangzhou, Zhejiang, Peoples R China
关键词
REACTIVE PROTEIN/ALBUMIN RATIO; TO-MONOCYTE RATIO; CELL LUNG-CANCER; FREE SURVIVAL; D-DIMER; FIBRINOGEN; INFLAMMATION; OUTCOMES; THERAPY; TAXANES;
D O I
10.1245/s10434-019-07655-7
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background. Triple-negative breast cancer (TNBC) patients who achieve a pathologic complete response (pCR) after neoadjuvant chemotherapy (NAC) have better prognoses. Objective. This study aimed to develop an intuitive nomogram based on simple laboratory indexes to predict the pCR of standard NAC in TNBC patients. Methods. A total of 80 TNBC patients who received eight cycles of thrice-weekly standard NAC (anthracycline and cyclophosphamide followed by taxane) and subsequently underwent surgery in Zhejiang Cancer Hospital were retrospectively enrolled, and data on their pretreatment clinical features and multiple simple laboratory indexes were collected. The optimal cut-off values of the laboratory indexes were determined by the Youden index using receiver operating characteristic (ROC) curve analyses. Forward stepwise logistic regression (likelihood ratio) analysis was applied to identify predictive factors for a pCR of NAC. A nomogram was then developed according to the logistic model, and internally validated using the bootstrap resampling method. Results. pCR was achieved in 39 (48.8%) patients after NAC. Multivariate analysis identified four independent indicators: clinical tumor stage, lymphocyte to monocyte ratio, fibrinogen level, and D-dimer level. The nomogram established based on these factors showed its discriminatory ability, with an area under the curve (AUC) of 0.803 (95% confidence interval 0.706-0.899) and a bias-corrected AUC of 0.771. The calibration curve and Hosmer-Lemeshow test showed that the predictive ability of the nomogram was a good fit to actual observation. Conclusions. The nomogram proposed in the present study exhibited a sufficient discriminatory ability for predicting pCR of NAC in TNBC patients.
引用
收藏
页码:3912 / 3919
页数:8
相关论文
共 50 条
  • [21] Laboratory indicators predict axillary nodal pathologic complete response after neoadjuvant therapy in breast cancer
    Chen, Peng
    Zhao, Tong
    Bi, Zhao
    Zhang, Zhao-Peng
    Xie, Li
    Liu, Yan-Bing
    Song, Xing-Guo
    Song, Xian-Rang
    Wang, Chun-Jian
    Wang, Yong-Sheng
    FUTURE ONCOLOGY, 2021, 17 (19) : 2449 - 2460
  • [22] Comprehensive genomic profiling can predict response to neoadjuvant chemotherapy in triple-negative breast cancer
    Drobniene, Monika
    Breimelyte, Dominyka
    Sadzeviciene, Ieva
    Sabaliauskaite, Rasa
    Valkiuniene, Ruta Barbora
    Meskauskas, Raimundas
    Dabkeviciene, Daiva
    Jarmalaite, Sonata
    BREAST, 2025, 80
  • [23] Pathologic Response After Neoadjuvant Chemotherapy Predicts Locoregional Control in Patients With Triple-Negative Breast Cancer
    Gillespie, E.
    Chen, V. E.
    Murphy, J.
    Yashar, C. M.
    Lu, S. M.
    Einck, J. P.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S241 - S241
  • [24] Pretreatment Sarcopenia and MRI-Based Radiomics to Predict the Response of Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer
    Guo, Jiamin
    Meng, Wenjun
    Li, Qian
    Zheng, Yichen
    Yin, Hongkun
    Liu, Ying
    Zhao, Shuang
    Ma, Ji
    BIOENGINEERING-BASEL, 2024, 11 (07):
  • [25] Neoadjuvant Chemotherapy Is Associated with Improved Survival Compared with Adjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer Only after Complete Pathologic Response
    Fisher, Carla S.
    Ma, Cynthia X.
    Gillanders, William E.
    Aft, Rebecca L.
    Eberlein, Timothy J.
    Gao, Feng
    Margenthaler, Julie A.
    ANNALS OF SURGICAL ONCOLOGY, 2012, 19 (01) : 253 - 258
  • [26] Neoadjuvant Chemotherapy Is Associated with Improved Survival Compared with Adjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer Only after Complete Pathologic Response
    Carla S. Fisher
    Cynthia X. Ma
    William E. Gillanders
    Rebecca L. Aft
    Timothy J. Eberlein
    Feng Gao
    Julie A. Margenthaler
    Annals of Surgical Oncology, 2012, 19 : 253 - 258
  • [27] Disparities Influence Pathologic Complete Response Rates After Neoadjuvant Chemotherapy In Triple Negative Breast Cancer
    Calvo, C.
    Colton, A.
    Hester, C. A.
    Xu, X.
    Zhu, H.
    Partain, N. S.
    Wooldridge, R.
    Farr, D.
    Huth, J.
    Leitch, M.
    ANNALS OF SURGICAL ONCOLOGY, 2019, 26 : S101 - S101
  • [28] Tumor Microenvironment Can Predict Chemotherapy Response of Patients with Triple-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy
    Kim, Dongjin
    Yu, Yeuni
    Jung, Ki Sun
    Kim, Yun Hak
    Kim, Jae-Joon
    CANCER RESEARCH AND TREATMENT, 2024, 56 (01): : 162 - 177
  • [29] Does pathologic complete response predict for outcome inBRCA mutation carriers with triple-negative breast cancer?
    Paluch-Shimon, Shani
    Friedman, Eitan
    Berger, Raanan
    Papa, Moshe Zvi
    Dadiani, Maya
    Friedman, Neil
    Shabtai, Moshe
    Zippel, Douglas
    Gutman, Mordechai
    Golan, Talia
    Catane, Raphael
    Yosepovich, Ady
    Modiano, Tami Mekel
    Kaufman, Bella
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [30] Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: Pathologic Complete Response and Survival after Long-Term Follow-Up
    Guiu, S.
    Arnould, L.
    Coudert, B.
    Liegard, M.
    Mayer, F.
    Favier, L.
    Fumoleau, P.
    CANCER RESEARCH, 2009, 69 (24) : 572S - 572S